Related Experiment Video
Updated: Jan 2, 2026

How to Measure Cortical Folding from MR Images: a Step-by-Step Tutorial to Compute Local Gyrification Index
Published on: January 2, 2012
Widespread Cortical Thickness Is Associated With Neuroactive Steroid Levels
Rajendra A Morey1,2,3, Sarah L Davis1,2, Courtney C Haswell1,2
1Mid-Atlantic Mental Illness Research, Education and Clinical Center, Durham VA Medical Center, U.S. Department of Veteran Affairs, Durham, NC, United States.
Higher levels of neuroactive steroids, like allopregnanolone and pregnenolone, correlate with increased gray matter thickness in key brain regions. This finding may aid in monitoring neuroregenerative therapies.
Area of Science:
- Neuroscience
- Endocrinology
- Radiology
Background:
- Neuroactive steroids possess regenerative and neuroprotective properties.
- Age-related decline in cortical thickness and neuroactive steroid levels is observed.
- Existing research lacks systematic examination of neuroactive steroid levels and in vivo cortical thickness in humans.
Purpose of the Study:
- To investigate the relationship between serum neuroactive steroid levels and in vivo cortical thickness.
- To identify specific brain regions where this association is present.
Main Methods:
- Assayed serum levels of seven neuroactive steroids in 143 US military veterans.
- Utilized high-resolution structural MRI for cortical surface parcellation into 148 regions.
- Employed regression modeling and False Discovery Rate (FDR) correction to analyze associations.
Main Results:
- Positive correlations were found between allopregnanolone and pregnenolone levels and gray matter thickness.
- These associations were observed in multiple regions of the cingulate, parietal, and occipital association cortices.
- Statistical significance was confirmed with FDR correction (r = 0.20-0.47; p < 0.05).
Conclusions:
- Serum neuroactive steroid levels are positively associated with gray matter cortical thickness in several brain areas.
- These findings suggest potential biomarkers for monitoring therapeutic interventions.
- Further confirmation is needed to establish clinical utility in neuroregenerative therapy studies.
More Related Videos
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
05:17BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABAA Receptor Presentation in the Rodent Brain
Published on: May 26, 2023
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Drugs Affecting Neurotransmitter Release or Uptake
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Neurochemical Transmission: Sites of Drug Action
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists